Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

InxMed Adds $15 Million B+ Funding for China/US Pivotal Trials of FAK Inhibitor

publication date: May 9, 2022

Nanjing InxMed announced a $15 million B+ funding round to develop its novel therapies that target the stroma microenvironment and drug resistance for hard-to-treat solid tumors. InxMed will use the funds for US/China clinical trials of its lead drug, IN10018, a selective adenosine triphosphate competitive FAK inhibitor. InxMed believes the candidate will prove to be effective alone and in combination with immunotherapies, chemotherapies and targeted therapies. The Series B+ round was funded entirely by Hyfinity Investments. Earlier this year, InxMed completed a $50 million B round. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio? News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China